Please login to the form below

Not currently logged in
Email:
Password:

Ipsen promotes Alexis Vandier as general manager, France

He will also join the French biopharma group’s global speciality leadership team

Alexis VandierParis-based biopharmaceutical group Ipsen has appointed Alexis Vandier as its new general manager for the France region.

In his new role, Vandier will be responsible for leading Ipsen’s teams in France, driving both the consumer healthcare and speciality care businesses in Ipsen’s home market.

Reporting to Ipsen’s executive vice president, Harout Semerjian, Vandier will also become a member of the company's global speciality care division.

Semerjian said: “I am convinced that Alexis’ strategic thinking, leadership skills, broad experience drive for exceptional results will help the French organisation rise to the next level as we pursue ambitious goals in both speciality care and consumer health care businesses for the patients’ benefit.”

Vandier has served Ipsen for seven years in senior roles including corporate strategic planning and business development, and he has spent the past four years in Ipsen’s consumer healthcare business reorganising its global business unit.

Prior to joining Ipsen, Vandier spent 12 years at Sanofi in a variety of finance, sales, marketing, corporate strategy and business development positions.

21st November 2017

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
claire@dovetailstrategies.com

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
The heavy toll of COVID-19 on cancer patients
We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...

Infographics